Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 7HR+/HER2- Advanced Breast Cancer 2Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1HER2-positive Breast Cancer 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

dalpiciclib 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × HR+/HER2- Advanced Breast Cancer × dalpiciclib × Clear all
NCT06556862 2025-08-13

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Beijing 302 Hospital

Phase 2 Not yet recruiting
155 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

NCT06711094 2024-12-02

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Fujian Medical University

Phase NA Not yet recruiting
52 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡